Please login to the form below

Not currently logged in
Email:
Password:

Tourette's syndrome

This page shows the latest Tourette's syndrome news and features for those working in and with pharma, biotech and healthcare.

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine says it is also expecting to report results for a trial of valbenazine in children with Tourette's syndrome next month, although an earlier study in adults failed to show ... If positive, Neurocrine is hoping to start a phase III trial in

Latest news

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Teva needs that kind of return, having forked out $3.5bn for SD-809's developer Auspex Pharma in 2015. ... Both companies are also exploring the use of their respective drugs to prevent tics associated with Tourette's syndrome.

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    Teva has been knocked back by an FDA decision not to approve deutetrabenazine, its candidate drug for chorea associated with Huntington's disease. ... and tics associated with Tourette's syndrome.

  • Neurocrine plans movement disorder drug filing in 2016 Neurocrine plans movement disorder drug filing in 2016

    Analysts at Nomura recently predicted that NBI-98854 could eventually become a $1.5bn product, even without a possible follow-up indication in Tourette's syndrome - and the announcement of the ... Neurocrine expects to complete its first phase Ib trial

  • Teva drug shows promise in movement disorder Teva drug shows promise in movement disorder

    in the US," said the trial's principal investigator Hubert Fernandez of the Cleveland Clinic. ... It also has late-stage trials ongoing in chorea associated with Tourette's syndrome. .

  • FDA starts review of Lundbeck’s antipsychotic aripiprazole

    This slow-down is expected to continue following the loss of patent protection on Eli Lilly's big-selling Zyprexa (olanzapine) brand earlier this year in the US. ... Otsuka is also developing a once-weekly oral formulation of aripiprazole which recently

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics